12-Jul-2019 - Agilent Technologies Inc.

Agilent to Acquire BioTek

Agilent Technologies Inc. announced it has signed a definitive agreement to acquire privately-owned BioTek Instruments for $1.165 billion. With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately $1.05 billion.

The transaction is expected to be completed in Agilent's fiscal fourth quarter of this year, subject to regulatory approvals and customary closing conditions. Agilent expects the acquisition will be accretive to non-GAAP earnings per share, contributing $0.02-$0.04 for fiscal year 2020, and compounding growth thereafter.

"BioTek represents a strong strategic fit with Agilent," said Mike McMullen, Agilent president and CEO. "The combination of these two companies will accelerate our multi-year growth strategy to expand our position in cell analysis. This is another example of Agilent investing in high-growth segments of the life sciences market to serve new and existing customers. Agilent is committed to continuing operations in Vermont and retaining the great team of nearly 500 employees that have been at the core of BioTek's 50-year history of excellence and success."

Expanding Portfolio and Leadership in Cell Analysis

Agilent entered the cell analysis segment in 2015 with the acquisition of Seahorse Bioscience. Agilent Seahorse XF technology was a leap in the evolution of cellular metabolism analysis, allowing researchers to better understand metabolic profiles in live cells.

In January 2018, Agilent broadened its portfolio of cell analysis solutions through the acquisition of Luxcel Biosciences.

In September 2018, Agilent differentiated its portfolio further through the acquisition of ACEA Biosciences. Upon closing, the size of Agilent's cell analysis business will be in excess of $250 million in annual revenues.

"By combining BioTek's offerings with Agilent's, we will deliver a breadth of differentiated workflows, enabling customers to obtain deeper, more reliable insights across a variety of cell analysis applications," said Jacob Thaysen, president of Agilent's Life Sciences and Applied Markets Group. "This positions Agilent well in the large and growing immuno-oncology and immunotherapy markets and expands our presence in biopharma, academia and research as customers seek to understand complex cellular environments and interactions."

Facts, background information, dossiers
  • acquisitions
  • Agilent Technologies
  • BioTek Instruments
More about Agilent
More about BioTek
  • News

    BioTek Instruments Receives Vermont Business Growth Award for Technology

    BioTek Instruments will be recognized as a 2016 Vermont Business Growth Award winner in the Technology category at a ceremony to be held September 12, 2016 at the Hilton Burlington hotel, in Burlington, Vermont. This annual award, formerly known as the 5x5x5 Growth Award, is sponsored by Ve ... more

    BioTek Instruments embarks on major site expansion

    BioTek Instruments celebrated the start of a $4 million, 22,000 square foot facility expansion during a company-wide event on Monday, July 18, featuring honorable guests Vermont Senator Patrick Leahy, Congressman Peter Welch, Governor Peter Shumlin, and Lt. Governor Phil Scott. The increase ... more

    BioTek Introduces New General Manager in Germany

    BioTek Instruments welcomes Dr. Frank Siefert as General Manager of BioTek Germany and the company’s European Coordination Center, which provides service applications and technical support throughout the continent. Dr. Siefert will be responsible for managing day-to-day operations in German ... more

  • Products

    Ready for any assay

    The Cytation 7 Multi-Detection Reader for Cell Imaging offers a unique level of automated microscopy and multi-mode detection in one easy-to-use instrument more

    One for All - Precise, Accurate and Modular

    MultiFlo FX, the automated reagent dispenser for 6- to 1536-well microplates, makes it easy for users to add features that meet their individual needs more

  • Videos

    Ready for any assay

    The Cytation 7 Multi-Detection Reader for Cell Imaging offers a unique level of automated microscopy and multi-mode detection in one easy-to-use instrument more

    One for All - Precise, Accurate and Modular

    MultiFlo FX, the automated reagent dispenser for 6- to 1536-well microplates, makes it easy for users to add features that meet their individual needs more

  • Companies

    BioTek Instruments GmbH

    BioTek is a leading developer and supplier of high-value microplate instrumentation and software solutions. Our instrumentation is used to accelerate the drug discovery process, to advance discoveries in genomics and proteomics, and to aid in the advancement of life science research. As par ... more

    BioTek Instruments, Inc.

    BioTek Instruments, Inc. is a global leader in the development, manufacture and sale of microplate instrumentation and software. more

    BioTek Instruments (Switzerland) GmbH

    BioTek Instruments, Inc., is a global leader in the development, manufacture and sale of microplate instrumentation and software used to aid in the advancement of life science research and to facilitate the drug discovery process. Our instrumentation provides rapid and cost-effective analy ... more